Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024
ODI Pharma AB (“ODI” or the “Company”) announces today that the preliminary financial results for the third quarter of fiscal year 2023/2024 are expected to surpass current market expectations. Initial figures for this period indicate that revenues will exceed SEK 13.5 million. This growth mainly comes from an increase in orders following our strategic partnership in Eastern Europe."These extraordinary results mark a turning point in ODI Pharma’s operations and demonstrate the potential of our business model. The substantial increase in orders, following our collaboration with Synoptis